Ads
related to: factor viii lab results explained- Surgical Procedure Info
Learn about treatment plans
for planned surgical procedures.
- Treatment Dosing
Learn about the personalized dosing
this treatment option offers.
- Find the CES Nearest You
Community education specialists are
available for patient support.
- Treatment Insights
Learn about a Factor VIII treatment
option for Hemophilia A.
- Prophylactic Treatment
Discover a prophylactic treatment
option for Hemophilia A.
- Treatment Safety
Read about the safety of this
Hemophilia A treatment option.
- Surgical Procedure Info
Search results
Results From The WOW.Com Content Network
Coagulation factor VIII (Factor VIII, FVIII, also known as anti-hemophilic factor (AHF)) is an essential blood clotting protein. In humans, it is encoded by F8 gene . [ 5 ] [ 6 ] Defects in this gene result in hemophilia A , an X-linked bleeding disorder .
Fresh normal plasma has all the blood coagulation factors with normal levels. If the problem is a simple factor deficiency, mixing the patient plasma 1:1 with plasma that contains 100% of the normal factor level results in a level ≥50% in the mixture (say the patient has an activity of 0%; the average of 100% + 0% = 50%). [3]
Hemophilia A causes a deficiency in Factor VIII, a protein required for blood clotting. Factor VIII injections are a common treatment to prevent or stop bleeding in people with hemophilia A. [1] Contamination of these and other products caused large numbers of hemophiliacs to become infected with HIV and hepatitis C.
Treatment and prevention of bleeding episodes is done primarily by replacing the missing blood clotting factors using "synthetic" or "non-human derived" factor products such as recombinant factor VIII. [24] Factor products work by replacing the missing factor proteins, which can take place at home or in hospital. In the 1970s, haemophiliacs ...
Factor VIII is used in haemophilia A and factor IX in haemophilia B. Factor replacement can be either isolated from human plasma, recombinant, or a combination of the two. Some people develop antibodies (inhibitors) against the replacement factors given to them, so the amount of the factor has to be increased or non-human replacement products ...
Diagnosis of haemophilia A also includes a severity level, which can range from mild to severe based on the amount of active and functioning factor VIII detected in the blood. Factor VIII levels do not typically change throughout an individual's lifetime. Severe haemophilia A is the most common severity, occurring in the majority of affected ...
The future of laboratory diagnostics are headed toward lab-on-a-chip technology, which will bring the laboratory to the point-of-care. This involves integration of all of the steps in the analytical process, from the initial removal of plasma from whole blood to the final analytical result, on a small microfluidic device.
A purified factor VIII concentrate is made from human blood plasma. [14] A recombinant version is also available. [13] People may develop antibodies to factor VIII such that this medication becomes less effective. [15] Factor VIII was first identified in the 1940s and became available as a medication in the 1960s.